WO2017172929A1 - Peptides bactéricides et leurs utilisations - Google Patents

Peptides bactéricides et leurs utilisations Download PDF

Info

Publication number
WO2017172929A1
WO2017172929A1 PCT/US2017/024766 US2017024766W WO2017172929A1 WO 2017172929 A1 WO2017172929 A1 WO 2017172929A1 US 2017024766 W US2017024766 W US 2017024766W WO 2017172929 A1 WO2017172929 A1 WO 2017172929A1
Authority
WO
WIPO (PCT)
Prior art keywords
antimicrobial peptide
amino acid
seq
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
PCT/US2017/024766
Other languages
English (en)
Inventor
C. Cheng Kao
Original Assignee
Indiana University Research And Technology Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indiana University Research And Technology Corporation filed Critical Indiana University Research And Technology Corporation
Publication of WO2017172929A1 publication Critical patent/WO2017172929A1/fr
Priority to US16/146,165 priority Critical patent/US10624947B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • Vibrios are Gram-negative bacteria that occur naturally in marine
  • Vibrios are recognized as a potential fish pathogen that are capable of spreading quickly when fish are in close contact to one another.
  • the infected fish may display lethargy, loss of appetite, and/or have necrotic sores.
  • a common method for preventing a Vibrios infection and for treating fish infected by Vibrios is to provide antibiotics in the water.
  • Vibrio bacteria live in saltwater. As such, consuming raw or undercooked shellfish, particularly oysters, can lead to vibriosis. It is documented that Vibrios are associated with uncooked shellfish and fish, which has had particularly significant consequences on foodborne illness. For example, several species of Vibrio, including Vibrio parahaemolyticus, are known to cause illness. Other potential human pathogens include V. vulnificus and V. cholera that can cause gastrointestinal illness. Symptoms consist of mild to moderate diarrhea, but can sometimes be severe, especially if the bacteria enter the bloodstream.
  • Resistance to antimicrobial drugs is a natural phenomenon. As bacteria and other microbes are exposed to antibiotics, they will eventually develop resistance through random mutations and by transferring resistance genes among themselves. Therefore, continually developing new drugs and judicious use of the available drugs is required.
  • Antibiotic resistance can arise through the overuse, or improper use, of antibiotics in both humans and animals. On the animal side, the concern centers on antibiotics provided to entire herds to either prevent disease or promote growth. In half of the countries in the world, including the United States and Canada, antibiotics are still used as growth promoters.
  • Resistance that arises in animals could affect humans in two ways.
  • Food- borne pathogens could develop their resistance in animals before going on to infect people via the food supply.
  • resistance genes could be transferred from animal bacteria to human pathogens through a process known as horizontal gene transfer, where genetic material is swapped between neighboring bacteria. In either scenario food production safety and human health will be jeopardized by antibiotic resistant bacteria.
  • compositions of antimicrobial peptides comprising compositions of antimicrobial peptides.
  • the antimicrobial peptides effectively kill various Gram-negative bacteria, particularly Vibrios bacteria strains within the genus.
  • an antimicrobial peptide comprises an amino acid sequence of XiX 2 X 3 X 4 X 5 X6RKKX 7 KKLX 8 KKLSPVIPLLX 9 XioXii (SEQ ID NO: 20), wherein Xi is a non-polar amino acid or absent, X 2 is a basic amino acid or absent, X 3 is a non-polar amino acid or absent, X 4 is a basic amino acid or absent, X5 is a basic amino acid or absent, X 6 is a non-polar amino acid, X 7 is a non-polar amino acid, X 8 is a non-polar amino acid, X9 is a basic amino acid or absent, X 10 is a non-polar amino acid or absent, and X 11 is a non-polar amino acid or absent; or a pharmaceutically acceptable salt thereof.
  • an antimicrobial peptide comprises an amino acid sequence of RGLRRLGRKIAHG VKKX 1 2 GPT VLRIIRIAGX 13 (SEQ ID NO: 21), wherein Xi 2 is a polar amino acid or a non-polar amino acid and X13 is a polar amino acid or absent; or a pharmaceutically acceptable salt thereof.
  • compositions for killing foodborne bacteria found in seafood are selected from the peptides group consisting of SEQ ID NOs: 11- 13 (BMAP-27A, BMAP-27B and BMAP-27C), SEQ ID NOs: 15-17 (SMAP-29B, SMAP-29C and SMAP-29D), and SEQ ID NOs. 18-19 (BMAP-24 and B22).
  • the aforementioned peptide is BMAP-27A.
  • the aforementioned peptide is BMAP-27B.
  • the aforementioned peptide is BMAP-27C.
  • the aforementioned peptide is SMAP-29B.
  • the aforementioned peptide is SMAP-29C.
  • the aforementioned peptide is SMAP-29D.
  • the aforementioned peptide is BMAP-24.
  • the aforementioned peptide is B22.
  • This disclosure further provides a method of sterilizing raw seafood.
  • the method comprises the steps of:
  • aforementioned seafood source with effective amount of at least one peptide selected from the group consisting of SEQ ID NOs: 11-13 (BMAP-27A, BMAP- 27B and BMAP-27C) SEQ ID NOs: 15-17 (SMAP-29B, SMAP-29C and SMAP-29D), and SEQ ID NOs. 18-19 (BMAP-24 and B22), wherein the selected peptide kills aforementioned Gram-negative bacteria in the food source.
  • SEQ ID NOs: 11-13 BMAP-27A, BMAP- 27B and BMAP-27C
  • SEQ ID NOs: 15-17 SMAP-29B, SMAP-29C and SMAP-29D
  • SEQ ID NOs. 18-19 BMAP-24 and B22
  • the aforementioned Gram-negative bacteria are
  • the aforementioned Gram-negative bacteria are a species in the Vibrios genus, an Escherichia coli, a Klebsiella pneumoniae, a Pseudomonas aeruginosa, a Serratia marcescens, or a mixture thereof.
  • the aforementioned Gram-negative bacteria are selected from the group consisting of V. cholerae (the causative agent of cholera), V. parahaemolyticus, V. vulnificus, and V. fischeri. In one preferred embodiment, the aforementioned Gram-negative bacteria are V. fischeri.
  • the aforementioned seafood is a fish or shellfish.
  • the aforementioned at least one peptide is degradable to amino acids along with said seafood consumption.
  • the aforementioned peptide is BMAP-27A.
  • the aforementioned peptide is BMAP-27B.
  • the aforementioned peptide is BMAP-27C.
  • the aforementioned peptide is SMAP-29B.
  • the aforementioned peptide is SMAP-29C.
  • the aforementioned peptide is SMAP-29D.
  • the aforementioned peptide is BMAP-24.
  • the aforementioned peptide is B22.
  • This disclosure further provides a method of treating Gram-negative bacteria infected animals in aquaculture.
  • the method comprises providing the infected animals effective amount of at least one peptide selected from the group consisting of SEQ ID NOs: 11-13 (BMAP-27A, BMAP-27B and BMAP-27C), SEQ ID NOs: 15-17 (SMAP-29B, SMAP-29C and SMAP-29D), and SEQ ID NOs: 18-19 (BMAP-24 and B22).
  • the aforementioned infected animals are grown from fresh water aquaculture.
  • the aforementioned Gram-negative bacteria are
  • a method of killing Gram-negative bacteria comprises contacting a Gram-negative bacteria with an antimicrobial peptide in accordance with the present disclosure; or a
  • a method of treating a Gram-negative bacterial infection in a subject in need thereof comprises administering to the subject an effective amount of an antimicrobial peptide according to the present disclosure; or a pharmaceutically acceptable salt thereof.
  • X 1 is a non-polar amino acid or absent
  • X 2 is a basic amino acid or absent
  • X 3 is a non-polar amino acid or absent
  • X 4 is a basic amino acid or absent
  • X5 is a basic amino acid or absent
  • X 6 is a non-polar amino acid
  • X 7 is a non-polar amino acid
  • X 8 is a non-polar amino acid
  • X9 is a basic amino acid or absent
  • X 10 is a non-polar amino acid or absent
  • Xn is a non-polar amino acid or absent; or a pharmaceutically acceptable salt thereof.
  • Xi is G or absent
  • X 2 is R or absent
  • X 3 is F
  • A or absent
  • X 4 is K or absent
  • X5 is R or absent, X 6 is F or L, X 7 is F or L, X 8 is F or A, X9 is H, K, or absent, X 10 is L or absent, Xn is G or absent, provided that when X 7 is F, X 6 is L; or a pharmaceutically salt thereof.
  • X 6 is a non-polar amino acid
  • X 7 is a non-polar amino acid
  • X 8 is a non-polar amino acid
  • X9 is a basic amino acid
  • X 10 is a non-polar amino acid
  • Xn is a non-polar amino acid; or a pharmaceutically acceptable salt thereof.
  • X 6 is F or L
  • X 7 is F or L
  • X 8 is F or A
  • X9 is H or K
  • X 10 is L
  • Xn is
  • Xi is a non-polar amino acid
  • X 2 is a basic amino acid
  • X 3 is a non- polar amino acid
  • X 4 is a basic amino acid
  • X5 is a basic amino acid
  • X 6 is a non-polar amino acid
  • X 7 is a non-polar amino acid
  • X 8 is a non-polar amino acid; or a pharmaceutically acceptable salt thereof.
  • Xi is G
  • X 2 is R
  • X 3 is F or A
  • X 4 is K
  • X5 is R
  • X 6 is F or L
  • X 7 is F or
  • X 8 is F or A, provided that when X 7 is F, X 6 is L; or a pharmaceutically salt thereof.
  • antimicrobial peptide of clause 1 or 2 wherein the antimicrobial peptide comprises a sequence that is at least 90%, at least 93%, or at least 95% identical to a sequence selected from the group consisting of SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 18, and SEQ ID NO: 19; or a pharmaceutically acceptable salt thereof.
  • antimicrobial peptide of clause 1 or 2 wherein the antimicrobial peptide comprises a sequence that is at least 90%, at least 93%, or at least 95% identical to a sequence selected from the group consisting of SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 18, and SEQ ID NO: 19; or a pharmaceutically acceptable salt thereof.
  • X 12 is a polar amino acid or a non-polar amino acid and X13 is a polar amino acid or absent; or a pharmaceutically acceptable salt thereof.
  • Xi3 is C; or a pharmaceutically acceptable salt thereof.
  • antimicrobial peptide of any one of clauses 23-25 wherein the antimicrobial peptide comprises a sequence that is at least 90%, at least 93%, or at least 95% identical to a sequence selected from the group consisting of SEQ ID NO: 15, SEQ ID NO: 16, and SEQ ID NO: 17; or a pharmaceutically acceptable salt thereof.
  • a method of providing sterilization to raw seafood comprising
  • Figures 1A-C show a general illustration of antimicrobial peptides.
  • Figure 1A shows a general illustration showing how antimicrobial peptides may prevent infections (selected from Zasloff, Nature Medicine 2006).
  • Figure IB shows a space-filling model of an antimicrobial peptide.
  • Figure 1C shows a pictorial representation of an antimicrobial peptide (selected from Wang et al., J. Biol. Chem. 2008).
  • Figures 2A-D show a proposed mechanism of bacterial killing by an antimicrobial peptide (adapted from Nguyen et al. 2011. Trends in Biotechnology 29, 464).
  • Figure 2A shows antimicrobial peptides undergo a conformational change near a bacterial membrane.
  • Figure 2B shows a toroidal pore formed in the bacterial membrane.
  • Figure 2C shows a disordered toroidal pore formed in a bacterial membrane.
  • Figure 2D shows non-lytic membrane depolarization in a bacterial membrane.
  • Figure 3A-B show cathelicidin peptides produced by different animals.
  • FIG. 3A shows a phylogenetic relationship of cathelicidin peptides from mammals.
  • the Figure is derived from results of Zanetti et al (J. Leuk. Biol. 2004).
  • Figure 3B shows the names, lengths, and sequences of antimicrobial peptides with the residues predicted to form an alpha- helix underlined (SEQ ID NOS 1-9, respectively, in order of appearance).
  • Figures 4A-D show SMAP-29 and variants thereof kill bacteria and have reduced cytotoxicity.
  • Figure 4A shows SMAP-29 and variants thereof effectively kill bacteria (SEQ ID NOS 14, 15 and 17, respectively, in order of appearance).
  • the bacterial strains tested are: Klebsiella pneumoniae (K. p.), Serratia marcescens (S. m.), Enterobacter cloacae (E. cl.), Escherichia coli (E. co.), and Pseudomonas aeruginosa (P. a.).
  • Figure 4B shows RBC lysis does not correlate with antibacterial activity.
  • FIG. 4C shows the effective antibacterial activity does not correlate with higher mammalian cytotoxicity. Cultured human cells were tested with antimicrobial peptides LL-37, SMAP-29, SMAP-29B, and SMAP-29D. MTT assays indicated no increased cytotoxicity compared to the controls.
  • Figure 4D shows the ability of SMAP-29 and variants thereof to enhance signal transduction by TLR3 and to suppress signal transduction by TLR4. IL-6 levels secreted by the cells were quantified using an ELISA assay.
  • Figure 4E shows the ability of the SMAP29 series of peptides for enhancement of signal transduction by TLR3 and to suppress signal transduction by TLR4. IL-6 levels secreted by the cells were quantified using an ELISA assay.
  • Figures 5A-E show BMAP-27 variants thereof kill bacteria and have reduced cytotoxicity.
  • Figure 5A shows BMAP-27 and variants thereof effectively kill bacteria (SEQ ID NOS 10-13, respectively, in order of appearance).
  • the bacterial strains tested are:
  • Figure 5B shows RBC lysis does not correlate with antibacterial activity.
  • LL-37, BMAP-27, BMAP-27A, BMAP-27B and BMAP- 27C all had bacterial killing effects but showed decreased RBC lysis compared to the control H 2 0.
  • Figure 5C shows the effective antibacterial activity does not correlate with higher mammalian cytotoxicity. Cultured human cells were tested with the
  • FIG. 5D shows the ability of BMAP-27 and variants thereof enhance signal transduction by TLR3 and suppress signal transduction by TLR4. IL-6 levels secreted by the cells were quantified using an ELISA assay.
  • Figure 5E shows the ability of BMAP27 and variants thereof enhance signal transduction by TLR3 and suppress signal transduction by TLR4. IL-6 levels secreted by the cells were quantified using an ELISA assay.
  • Figures 6A-B shows the rate of bacterial killing by the antimicrobial peptides.
  • Figure 6A shows a comparison of SMAP-29D and BMAP-27B bacterial killing effect as compared the antibiotic Kanamycin.
  • Figure 6B shows SMAP-29D and BMAP-27B at 2 ⁇ concentration had exponentially reduced bacterial colony forming units within 5 min, measured on the bacteria strains.
  • Figure 7 shows multiple Vibrio species are highly sensitive to SMAP-29C.
  • Figure 8 shows SMAP-29D and BMAP-27B killing of V. angustum.
  • Figure 9 shows SMAP-29D and BMAP-27B killing of V. fischeri.
  • Figures 10A-B show V. vulnificus YJ016 growth curve in the absence and presence of antimicrobial peptides.
  • Figure 10A shows the growth curve in the presence of different concentrations of BMAP-27B.
  • Figure 10B shows the growth curve in the presence of different concentrations of SMAP-29D.
  • Figure 11 shows the mechanism of action of the antimicrobial peptides.
  • Phase contrast micrographs shows three representative V. vulnificus cells that were treated for 5 min with 4 ⁇ FAM-labeled SMAP-29D.
  • the DAPI stain is colored blue and the FAM-SMAP- 29D green.
  • Figures 12A-B show BMAP-27B and SMAP-29D can kill colistin-resistant E. coli.
  • Fig 12A shows colony growth of five Gram-negative bacteria treated with increasing concentrations of BMAP-27B, SMAP-29D, and colistin. lxlO 5 CFUs of the bacteria were incubated for 30 min with the concentration of the peptides or colistin shown.
  • Fig. 12B shows a quantitative analysis of the viable colonies formed by colistin-resistant bacteria.
  • E. coli Top 10/ pHNSHP45 or the parental strain Top 10 were incubated for 5 with either colistin, BMAP-27B, or SMAP-29D prior to plating to enumerate CFUs on MH agar.
  • the numbers are the means of three independent assays and those in parenthesis are the range for one standard deviation.
  • Figure 13 shows an analysis of truncated variants of BMAP-27B for bactericidal activity against E. coli harboring the mcr-1 resistance gene on a plasmid (SEQ ID NOS 12, 18 and 19, respectively, in order of appearance).
  • Each antimicrobial peptide was assayed at a final concentration of 2 ⁇ .
  • the number of viable bacterial colonies were determined by plating on a non-selective media and enumerated. Each result is the average of three independent assays.
  • the fold reduction in the colony forming units (CFU) was calculated by dividing the number of CFUs in the mock-treated sample with the number in the peptide-treated samples.
  • Figures 14A-B show that the antimicrobial peptides B22 and BMAP-24 do not enhance the activation of the production of proinflammatory cytokine IL-6 ( Figure 14A) and the proinflammatory cytokine IL-8 ( Figure 14B) through the Toll-like receptor 3 signaling pathway.
  • Lung epithelial BEAS-2B cells were induced with poly(LC) at 0.1 ⁇ g/ml and the amount of IL-6 secreted into the media 20 h later was assessed by ELISA. Where present, the antimicrobial peptide was at a final concentration of 2 ⁇ . Each result represents the mean and standard error of three independent assays.
  • Figure 15 shows the antimicrobial peptide B22 lyses fewer human red blood cells (hRBCs) and has limited cytotoxicity.
  • the amount of hemoglobin released was measured by the absorbance at 435 nM after a 60-minute incubation with the antimicrobial peptide.
  • the percentage of hRBC lysis was normalized to the amount hemoglobin released by the suspension of the hRBCs in deionized water.
  • the background amount of hRBC lysis was determined by adding phosphate buffered saline (PBS) at the same volume as 8 ⁇ of the peptide to the hRBC for 1 h.
  • PBS phosphate buffered saline
  • Figure 16 shows the antimicrobial peptide B22 can reduce the lethal sepsis by
  • Vibrio vulnificus The number of symptom-less mice in cages of 5 mice were recorded as a function of time. About 50 colony forming units of V. vulnificus were introduced into a surgical incision. The antimicrobial peptide B22 was introduced into the incision at 5 ⁇ 1 h after the introduction of V. vulnificus to the surgical incision.
  • an antimicrobial peptide comprises an amino acid sequence of XiX 2 X 3 X 4 X 5 X 6 RKKX 7 KKLX 8 KKLSPVIPLLX 9 XioXii (SEQ ID NO: 20), wherein Xi is a non-polar amino acid or absent, X 2 is a basic amino acid or absent, X 3 is a non-polar amino acid or absent, X 4 is a basic amino acid or absent, X5 is a basic amino acid or absent, X 6 is a non-polar amino acid, X 7 is a non-polar amino acid, X 8 is a non-polar amino acid, X9 is a basic amino acid or absent, X10 is a non-polar amino acid or absent, and X11 is a non-polar amino acid or absent; or a pharmaceutically acceptable salt thereof.
  • an antimicrobial peptide comprises an amino acid sequence of XiX 2 X 3 X 4 X 5 X 6 RKKX 7 KKLX 8 KKLSPVIPLLX 9 XioXii (SEQ ID NO: 24), wherein Xi is G or absent, X 2 is R or absent, X 3 is F, A, or absent, X 4 is K or absent, X5 is R or absent, X 6 is F or L, X 7 is F or L, X 8 is F or A, X9 is H, K, or absent, X10 is L or absent, and X11 is G or absent, provided that when X 7 is F, X 6 is L; or a pharmaceutically salt thereof.
  • an antimicrobial peptide comprises an amino acid sequence of X 6 RKKX 7 KKLX 8 KKLSPVIPLLX 9 Xi 0 Xii (SEQ ID NO: 22), wherein X 6 is a non-polar amino acid, X 7 is a non-polar amino acid, X 8 is a non-polar amino acid, X9 is a basic amino acid, X10 is a non-polar amino acid, and Xn is a non-polar amino acid; or a pharmaceutically acceptable salt thereof.
  • an antimicrobial peptide comprises an amino acid sequence of X 6 RKKX 7 KKLX 8 KKLSPVIPLLX 9 XioXii (SEQ ID NO: 25), wherein X 6 is F or L, X 7 is F or L, X 8 is F or A, X9 is H or K, X10 is L, and Xn is G, provided that when X 7 is F, X 6 is L; or a pharmaceutically salt thereof.
  • an antimicrobial peptide comprises an amino acid sequence of XiX 2 X 3 X 4 X 5 X 6 RKKX 7 KKLX 8 KKLSPVIPLL (SEQ ID NO: 23), wherein Xi is a non-polar amino acid, X 2 is a basic amino acid, X 3 is a non-polar amino acid, X 4 is a basic amino acid, X5 is a basic amino acid, X 6 is a non-polar amino acid, X 7 is a non-polar amino acid, and X 8 is a non-polar amino acid; or a pharmaceutically acceptable salt thereof.
  • an antimicrobial peptide comprises an amino acid sequence of XiX 2 X 3 X 4 X 5 X 6 RKKX 7 KKLX 8 KKLSPVIPLL (SEQ ID NO: 26), wherein Xi is G, X 2 is R, X 3 is F or A, X 4 is K, X5 is R, X 6 is F or L, X 7 is F or L, and X 8 is F or A, provided that when X 7 is F, X 6 is L; or a pharmaceutically salt thereof.
  • an antimicrobial peptide comprises an amino acid sequence of RGLRRLGRKIAHG VKKX 1 2 GPT VLRIIRIAGX i 3 (SEQ ID NO: 21), wherein Xi 2 is a polar amino acid or a non-polar amino acid and X is a polar amino acid or absent; or a pharmaceutically acceptable salt thereof.
  • an antimicrobial peptide comprises an amino acid sequence of RGLRRLGRKIAHG VKKX 1 2 GPT VLRIIRIAGX i 3 (SEQ ID NO: 27), wherein Xi 2 is Y, C, or L and Xi 3 is C or absent, provided that when Xi 2 is Y, Xi 3 is C; or a pharmaceutically acceptable salt thereof.
  • an antimicrobial peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, and a combination thereof.
  • Cathelicidin-related antimicrobial peptides are a family of peptides produced by macrophages and polymorphonuclear leukocytes (PMNs), and epithelial cells such as keratinocytes. cathelicidins serve a critical role in mammalian innate immune defense against invasive bacterial infection.
  • the peptides of cathelicidin family are classified as
  • Antimicrobial peptides are produced by organisms in all three kingdoms of life on earth to decrease the establishment of other microbes.
  • Cathelicidins are a class of peptides typically of -25-40 amino acids in length that have a high frequency of basic amino acids. They interact with the membranes of susceptible bacteria, form higher order structures to cause leakage of ions and the death of the bacteria. Cathelicidins could also bind bacterial cell wall materials, including lipopoly saccharide (LPS) molecules that are potent inducers of the inflammatory responses. These properties have made antimicrobial peptides attractive molecules to replace antibiotics.
  • LPS lipopoly saccharide
  • LL-37 is the only cathelicidin antimicrobial peptide produced by humans.
  • LL-37 is generated by proteolytic cleavage of the C-terminal portion of the hCAP- 18 protein.
  • LL-37 has a large array of biological activities. For example, in addition to suppressing bacterial infection and suppressing the pro-inflammatory responses, LL-37 can promote wound healing and decreasing fibrosis.
  • Cathelicidin peptides have been isolated from many different species of mammals, including but not limited to humans, monkeys, mice, rats, rabbits, guinea pigs, pandas, pigs, cattle, frogs, sheep, goats, chickens, and horses. Some species produce more than one Cathelicidins. Illustratively, cathelicidins are enriched for positively-charged amino acids, but the sequences for the cathelicidins produced by different animals vary.
  • cathelicidins include but not limited to the following:
  • Vibrio is a genus of Gram-negative bacteria, possessing a curved-rod shape
  • Vibrio Several species of Vibrio are human pathogens. Most disease-causing strains are associated with gastroenteritis, but can also infect open wounds and cause septicemia. They can be carried by numerous marine animals, such as crabs or prawns, and have been known to cause fatal infections in humans during exposure. Pathogenic Vibrio species include V. cholerae (the causative agent of cholera), V. parahaemolyticus, and V. vulnificus. V. cholerae is generally transmitted by contaminated water. Pathogenic Vibrio species can cause foodborne illness (infection), usually associated with eating undercooked seafood. The pathogenic features can be linked to quorum sensing where bacteria are able to express their virulence factor via their signaling molecules.
  • V. vulnificus is an extremely virulent pathogen found in marine environments. V. vulnificus outbreaks commonly occur in warm climates and small, generally lethal, outbreaks occur regularly. An outbreak occurred in New Jersey after Hurricane Katrina, and several lethal cases occur most years in Florida. V. vulnificus can cause gastroenteritis when ingested in oysters, septicemia in undercooked shellfish, and necrotic wounds are found with 25% mortality, 50% with septicemia.
  • Cephalosporin and a Tetracycline Cephalosporin and a Tetracycline (Ceftriaxone and doxycycline).
  • V. parahaemolyticusis also associated with the Kanagawa phenomenon, in which strains isolated from human hosts (clinical isolates) are hemolytic on blood agar plates, while those isolated from nonhuman sources are not hemolytic.
  • Vibrio species are also zoonotic. Illustratively, many Vibrio can cause disease in fish and shellfish and are common causes of mortality among domestic marine life.
  • Antimicrobial peptides in accordance with the present disclosure are efficient at killing a number of foodborne Gram-negative bacteria.
  • the Gram- negative bacteria are particularly those found in the Vibrio genus.
  • the antimicrobial peptide has reduced cytotoxicity for human cells.
  • a very low concentration of an antimicrobial peptide in accordance with the present disclosure is required to effectively kill various Gram-negative bacteria.
  • selective peptides such as the SMAP-29 variants or the BMAP-27 variants are tested for their bacterial killing effects, the colony forming units for various Gram-negative bacteria, including E. cloacae 4080, E.
  • SMAP-29D and BMAP-27B efficiently kill V. angustum, V. fischeri, and V. vulnificus as shown in Figures 8-11.
  • antimicrobial peptides in accordance with the present have reduced cytotoxicity to human cells.
  • the induction of red blood cell lysis is decreased compared to other similar peptides, such as LL-37.
  • the TLR3/FLPR-1 mediated autoimmune response is reduced when IL-6 production was assessed in the presence of double-stranded RNA and these peptides.
  • toxin-related inflammation is inhibited by the presence of these selective antimicrobial peptides.
  • the cell metabolism rate in the presence and absence of these antimicrobial peptides are not distinguishable, as shown for example, in Figures 4C and 5C.
  • antimicrobial peptides are degradable to become non-toxic amino acids. It is contemplated that these antimicrobial peptides can be used to treat raw seafood that is infected by a Gram- negative bacterium.
  • the antimicrobial peptides may be used to treat aquaculture.
  • these antimicrobial peptides can also be used in the fish pond to prevent or cure infections in farm-raised fish or shellfish, etc.
  • One advantage of such use is that the peptides do not need to be removed after the treatment since it can be degraded into non-toxic amino acid.
  • the application of these identified antimicrobial peptides can become a useful tool in the food processing industry.
  • Vibrios associated with uncooked shellfish and fish have had particularly significant consequences on foodborne illness.
  • the peptides produced in this disclosure can be used to decrease the bacterial load and render uncooked shellfish and fish safer for consumption.
  • antimicrobial peptides in accordance with the present disclosure can be used to treat farm-harvested or wild-caught seafood.
  • the seafood may be a fish or a shellfish.
  • Illustrative shellfish include crabs, prawns, oysters, and clams.
  • antimicrobial peptides in accordance with the present disclosure can be used to treat an infection in a subject.
  • the infection is in a wound.
  • the infected wound may be treated by contacting the infected wound with a composition comprising an antimicrobial peptide or a
  • the antimicrobial peptides and variants thereof kill Gram- negative bacteria within minutes and effectively (with several orders of magnitude reduction in viable bacterial numbers). The mechanism of action is likely due to perforation of the bacterial membrane. The reduction in viable bacterial number will decrease the infection of the aquaculture product and potential consumers of the aquaculture product. Application of these anti-microbial peptides in seafood preparation and aquafarming is contemplated within this disclosure.
  • Antimicrobial peptides and variants thereof may comprise polar amino acids.
  • polar amino acids are selected from the group consisting of asparagine (Asn, N), cysteine (Cys, C), glutamine (Gin, Q), serine (Ser, S), threonine (Thr, T), and tyrosine (Tyr, Y). It should be understood that acceptable polar amino acid variants include D-amino acids, peptoids, synthetic peptides, and any suitable alternative thereof.
  • Antimicrobial peptides and variants thereof may comprise non-polar amino acids.
  • the non-polar amino acids are selected from the group consisting of alanine (Ala, A), glycine (Gly, G), isoleucine (He, I), leucine (Leu, L), methionine (Met, M), phenylalanine (Phe, F), proline (Pro, P), tryptophan (Trp, W), and valine (Val, V).
  • acceptable non-polar amino acid variants include D-amino acids, peptoids, synthetic peptides, and any suitable alternative thereof.
  • Antimicrobial peptides and variants thereof may comprise basic amino acids.
  • the basic amino acids are selected from the group consisting of arginine (Arg, R), lysine (Lys, K), and histidine (His, H).
  • the basic amino acids comprise functional groups capable of being positively charged at physiological pH.
  • Representative basic functional groups include amines, guanidines, and heteroaromatic rings capable of being ionized at physiological pH. It should be understood that acceptable basic amino acid variants include D-amino acids, peptoids, synthetic peptides, and any suitable alternative thereof.
  • Antimicrobial peptides and variants thereof may comprise acidic amino acids.
  • acidic amino acids are selected from aspartic acid (Asp, D) glutamic acid (Glu, E), and derivatives thereof.
  • acidic amino acids comprise carboxylates or any other common functional group that is negatively charged at
  • acceptable acidic amino acid variants include D-amino acids, peptoids, synthetic peptides, and any suitable alternative thereof.
  • peptides sometimes called antimicrobial peptides, kill
  • the Gram-negative bacteria are selected from the group consisting of Vibrios genus, an Escherichia coli, an Enterobacter cloacae, an Enter ococcus faecalis, & Klebsiella pneumoniae, a Serratia marcescens, a Pseudomonas aeruginosa, and a mixture thereof.
  • the Gram-negative bacteria are selected from the group consisting of Vibrios genus, an Escherichia coli, a Klebsiella pneumoniae, a Pseudomonas aeruginosa, and a mixture thereof.
  • the Gram- negative bacteria is from the Vibrios genus. In some embodiments, the Gram- negative bacteria is an Escherichia coli. In some embodiments, the Gram-negative bacteria is an Enterobacter cloacae. In some embodiments, the Gram-negative bacteria is an Enterococcus faecalis. In some embodiments, the Gram-negative bacteria is a Klebsiella pneumoniae. In some embodiments, the Gram-negative bacteria is a a Serratia marcescens. In some embodiments, the Gram-negative bacteria is a Pseudomonas aeruginosa. fischeri
  • the Vibrios is selected from the group consisting of V. parahaemolyticus, V. vulnificus, V. fischeri. and V. harveyi. In some embodiments, the Vibrios is selected from the group consisting of V. parahaemolyticus, V. vulnificus, and V. fischeri. In some embodiments, the Vibrios is V. parahaemolyticus. In some embodiments, the Vibrios is V. vulnificus. In some embodiments, the Vibrios is V. fischeri. In some embodiments, the Vibrios is V. harveyi.
  • compositions described herein are provided.
  • Pharmaceutically acceptable salts of compositions described herein include acid addition and base salts thereof.
  • Suitable acid addition salts of the compositions described herein are formed from acids which form non-toxic salts.
  • Illustrative examples include the acetate, aspartate, benzoate, besylate, bicarbonate/carbonate, bisulphate/sulphate, borate, camsylate, citrate, edisylate, esylate, formate, fumarate, gluceptate, gluconate, glucuronate,
  • hydroiodide/iodide isethionate, lactate, malate, maleate, malonate, mesylate, methylsulphate, naphthylate, 2-napsylate, nicotinate, nitrate, orotate, oxalate, palmitate, pamoate,
  • phosphate/hydrogen phosphate/dihydrogen phosphate saccharate, stearate, succinate, tartrate, tosylate and trifluoroacetate salts.
  • Suitable base salts of the compositions described herein are formed from bases which form non-toxic salts.
  • Illustrative examples include the arginine, benzathine, calcium, choline, diethylamine, diolamine, glycine, lysine, magnesium, meglumine, olamine, potassium, sodium, tromethamine and zinc salts.
  • Hemisalts of acids and bases may also be formed, for example, hemisulphate and hemicalcium salts.
  • compositions are provided.
  • a pharmaceutical formulation comprises a peptide, sometimes called an antimicrobial peptide, described in accordance with the present disclosure.
  • the pharmaceutical formulation comprises any of the pharmaceutical compositions described herein.
  • the previously described embodiments of the pharmaceutical compositions are applicable to the pharmaceutical formulations described herein.
  • the type of formulation employed for the administration of the compounds may be dictated by the particular compounds employed, the type of pharmacokinetic profile desired from the route of administration and the compound(s), and the state of the patient.
  • the peptides may be formulated as pharmaceutical compositions for systemic administration. Such
  • compositions and processes for making the same are known in the art for both humans and non-human mammals. See, e.g., Remington: The Science and Practice of Pharmacy, (A. Gennaro, et ah, eds., 19 th ed., Mack Publishing Co., 1995).
  • the pharmaceutical formulations described herein further comprise a pharmaceutically acceptable carrier. In some embodiments, the pharmaceutical formulations described herein further comprise a pharmaceutically acceptable diluent. Diluent or carrier ingredients used in the pharmaceutical compositions containing peptides can be selected so that they do not diminish the desired effects of the peptide.
  • Suitable dosage forms include aqueous solutions of the peptides, for example, a solution in isotonic saline, 5% glucose or other well-known pharmaceutically acceptable liquid carriers such as alcohols, glycols, esters, and amides.
  • carrier refers to any ingredient other than the active component(s) in a formulation.
  • Pharmaceutically acceptable carriers are determined in part by the particular composition being administered, as well as by the particular method used to administer the composition ⁇ see, e.g., Remington's Pharmaceutical Sciences, 17th ed. (1985)).
  • the choice of carrier will to a large extent depend on factors such as the particular mode of administration, the effect of the carrier on solubility and stability, and the nature of the dosage form.
  • the carrier is a liquid carrier.
  • a “patient” as referred to herein can be a human patient or a veterinary patient, such as a domesticated animal ⁇ e.g., a pet) or a food animal.
  • the pharmaceutical formulations described herein optionally include one or more other therapeutic ingredients.
  • active ingredient or “therapeutic ingredient” refers to a therapeutically active compound, as well as any prodrugs thereof and pharmaceutically acceptable salts, hydrates, and solvates of the compound and the prodrugs.
  • Other active ingredients may be combined with the described peptides and may be either administered separately or in the same pharmaceutical formulation. The amount of other active ingredients to be given may be readily determined by one skilled in the art based upon therapy with described peptides.
  • the pharmaceutical formulations described herein are a single unit dose.
  • unit dose is a discrete amount of the composition comprising a predetermined amount of the described peptides.
  • the amount of the described peptides is generally equal to the dosage of the described peptides which would be
  • a dosage such as, for example, one-half or one-third of such a dosage.
  • parenteral formulations may be suitably formulated as a sterile non-aqueous solution or as a dried form to be used in conjunction with a suitable vehicle such as sterile, pyrogen-free water.
  • a suitable vehicle such as sterile, pyrogen-free water.
  • the preparation of parenteral formulations under sterile conditions, for example, by lyophilization, may readily be accomplished using standard pharmaceutical techniques well known to those skilled in the art.
  • the aqueous preparations according to the invention can be used to produce lyophilisates by conventional lyophilization or powders.
  • the preparations according to the invention are obtained again by dissolving the lyophilisates in water or other aqueous solutions.
  • lyophilization also known as freeze-drying, is a commonly employed technique for presenting proteins which serves to remove water from the protein preparation of interest. Lyophilization is a process by which the material to be dried is first frozen and then the ice or frozen solvent is removed by sublimation in a vacuum environment. An excipient may be included in pre-lyophilized formulations to enhance stability during the freeze-drying process and/or to improve the stability of the lyophilized product upon storage. For example, see Pikal, M. Biopharm. 3(9)26-30 (1990) and Arakawa et ah, Pharm. Res., 8(3):285-291 (1991).
  • the peptides in accordance with the present disclosure are described as antimicrobial peptides.
  • the solubility of the peptides in accordance with the present disclosure are described as antimicrobial peptides. In one embodiment, the solubility of the peptides in accordance with the present disclosure are described as antimicrobial peptides.
  • antimicrobial peptides used in the preparation of a parenteral formulation may be increased by the use of appropriate formulation techniques, such as the incorporation of solubility- enhancing agents.
  • formulations for parenteral administration may be formulated to be for immediate and/or modified release.
  • Modified release formulations include delayed, sustained, pulsed, controlled, targeted and programmed release formulations.
  • a peptide may be formulated as a solid, semi-solid, or thixotropic liquid for
  • the administration according to the described methods is performed as a single dose administration. In other embodiments, the
  • administration according to the described methods is performed as a multiple dose
  • the formulations can be presented in unit-dose or multi-dose sealed containers, such as ampules and vials.
  • the formulations can also be presented in syringes, such as prefilled syringes.
  • the dosages of the antimicrobial peptides can vary significantly depending on the patient condition and the severity of the disease to be treated.
  • the effective amount to be administered to a patient is based on body surface area, patient weight or mass, and physician assessment of patient condition.
  • the term "effective amount" refers to an amount of an antimicrobial peptide, peptide, drug, or pharmaceutical agent that elicits the biological or medicinal response in a subject (i.e. a tissue system, animal or human) that is being sought by a researcher, veterinarian, medical doctor or other clinician, which includes, but is not limited to, alleviation of the symptoms of the disease or disorder being treated.
  • the effective amount is that amount of an active which may treat or alleviate the disease or symptoms of the disease at a reasonable benefit/risk ratio applicable to any medical treatment.
  • the effective amount is that amount of an inactive prodrug which when converted through normal metabolic processes to produce an amount of active drug capable of eliciting the biological or medicinal response in a subject that is being sought.
  • the dose is advantageously selected with reference to any toxicity, or other undesirable side effects, that might occur during administration of one or more of the antimicrobial peptides described herein.
  • the co-therapies described herein may allow for the administration of lower doses of antimicrobial peptides that show such toxicity, or other undesirable side effects, where those lower doses are below thresholds of toxicity or lower in the therapeutic window than would otherwise be
  • administering includes all means of introducing the antimicrobial peptides and compositions described herein to the host animal, including, but are not limited to, oral (po), intravenous (iv), intramuscular (im), subcutaneous (sc), transdermal, inhalation, buccal, ocular, sublingual, vaginal, rectal, and the like.
  • the antimicrobial peptides and compositions described herein may be administered in unit dosage forms and/or formulations containing conventional nontoxic pharmaceutically-acceptable carriers, adjuvants, and/or vehicles.
  • composition refers to a mixture of one or more of the antimicrobial peptides described herein, or pharmaceutically acceptable salts, solvates, hydrates thereof, with other chemical components, such as pharmaceutically acceptable excipients.
  • pharmaceutical composition refers to a mixture of one or more of the antimicrobial peptides described herein, or pharmaceutically acceptable salts, solvates, hydrates thereof, with other chemical components, such as pharmaceutically acceptable excipients.
  • pharmaceutical composition refers to a mixture of one or more of the antimicrobial peptides described herein, or pharmaceutically acceptable salts, solvates, hydrates thereof, with other chemical components, such as pharmaceutically acceptable excipients.
  • the purpose of a pharmaceutical composition is to facilitate administration of an antimicrobial peptide to a subject.
  • compositions suitable for the delivery of antimicrobial peptides described and methods for their preparation will be readily apparent to those skilled in the art. Such compositions and methods for their preparation may be found, for example, in 'Remington's Pharmaceutical Sciences', 19th Edition (Mack Publishing Company, 1995).
  • Suitable dosages of the antimicrobial peptides can be determined by standard methods, for example by establishing dose-response curves in laboratory animal models or in humans in clinical trials.
  • suitable dosages of antimicrobial peptides can be determined by standard methods, for example by establishing dose-response curves in laboratory animal models or in humans in clinical trials.
  • suitable dosages of antimicrobial peptides can be determined by standard methods, for example by establishing dose-response curves in laboratory animal models or in humans in clinical trials.
  • suitable dosages of antimicrobial peptides can be determined by standard methods, for example by establishing dose-response curves in laboratory animal models or in humans in clinical trials.
  • administered in a single bolus or over time include from about 1 pg/kg to about 10 ⁇ g/kg, from about 1 pg/kg to about 1 ⁇ g/kg, from about 100 pg/kg to about 500 ng/kg, from about 1 pg/kg to about 1 ng/kg, from about 1 pg/kg to about 500 pg/kg, from about 100 pg/kg to about 500 ng/kg, from about 100 pg/kg to about 100 ng/kg, from about 1 ng/kg to about 10 mg/kg, from about 1 ng/kg to 1 mg/kg, from about 1 ng/kg to about 1 ⁇ g/kg, from about 1 ng/kg to about 500 ng/kg, from about 100 ng/kg to about 500 ⁇ g/kg, from about 100 ng/kg to about 500 ⁇ g/kg, from about 100 ng/kg to about 100 ⁇ g/kg, from about 1 ⁇ g/kg to about 500 ⁇ g/kg, or from
  • compositions for killing bacteria are a foodborne bacteria.
  • the bacteria is a foodborne bacteria found in seafood.
  • these compositions are selected from the peptides group consisting of SEQ ID NO: 11 (BMAP-27A), SEQ ID NO: 12 (BMAP- 27B), SEQ ID NO: 13 (BMAP-27C), SEQ ID NO: 15 (SMAP-29B), SEQ ID NO: 16 (SMAP- 29C), SEQ ID NO: 17 (SMAP-29D), SEQ ID NO: 18 (BMAP-24), and SEQ ID NO: 19 (B22).
  • siRNAs specific to FPRL1 sc-40123
  • EGFR sc-29301
  • a nonspecific control siRNA sc-37007
  • OptEIATM kit (BD Biosciences). A typical assay used 2 x 10 4 BEAS-2B cells/well grown for
  • MIC determination - Antimicrobial activity was determined using the broth microdilution method based on the general recommendation of the Clinical and Laboratory Standards Institute. Bacteria were grown in Mueller-Hinton broth at 37 °C until OD 6 25 reached 0.06, and then bacteria were further diluted into 1:20 for later use. Peptides were diluted in Mueller-Hinton broth at concentrations of 1, 2, 4, 8, 16, and 32 ⁇ g/ml. 10 microliter ( ⁇ ) of diluted bacteria was mixed with 90 ⁇ ⁇ of peptides at varying
  • the MIC is the lowest peptide concentration at which visible growth was inhibited.
  • the MIC value was determined at least twice in independent experiments and typically in 3-4 assays.
  • Hemolytic activity The hemolytic activities of peptides were determined using human red blood cells (hRBCs) (Innovative Research, Inc., cat. # IPLA-WB3-18103). The hRBCs were washed three times with PBS and then resuspended in PBS. The hRBCs solution was mixed with serial dilutions of the peptides in PBS buffer. The reaction mixtures were incubated for 45 min at 37 °C. After centrifugation at 94 x g for 10 min, the intact RBCs were pelleted and the hemoglobin released from RBCs was monitored by measuring the absorbance of the supernatant at 415 nm. The background level of absorbance was measured in sampled incubated with only PBS buffer. 100% hemolysis was determined in sampled incubated with water. The percentage of hemolysis was calculated according to the following equation.
  • Vibrios killing activity - Vibrios bacteria such as V. angustum or Vfischeri were cultured in LM at 30 °C.
  • the V. angustum culture was 200x diluted
  • V. fischeri culture was 40x diluted.
  • peptides SMAP-29 C and BMAP-27B at concentrations of 0.1 ⁇ , 0.5 ⁇ , and 1 ⁇ were prepared.
  • peptides SMAP-29 C and BMAP-27B at concentrations of 0.5 ⁇ , 1 ⁇ , and 2 ⁇ were prepared.
  • the peptides were incubated with the bacteria for 1 hour at 30 °C before plated into the bacteria culture (100 ⁇ ⁇ peptides and 20 ⁇ ⁇ mock). The culture and peptides were incubated overnight and Colony Forming Units (CFUs) were counted.
  • CFUs Colony Forming Units
  • Selective antimicrobial peptides have effective activity against various species of Gram-negative bacterium, particularly to fish/human pathogens from Vibrios genus, as will be exemplified below.
  • SMAP 29 and BMAP 27 variants have low concentration requirement (16 ⁇ g/ml) to effectively inhibit almost all or at least majority of Gram-negative strains of bacteria.
  • BMAP-27, BMAP-27A, and BMAP-27B were able to completely inhibit all tested strains at or below 16 ⁇ g/ml of peptide.
  • SMAP-29, SMAP-29B, and SMAP-29D were able to inhibit 16/19 strains tested at or below 16 ⁇ g/ml of peptide.
  • This provides an opportunity to use SMAP-29 and BMAP-27 variants to contain infection by the Gram- negative bacteria in applicable situations. For Gram-positive bacteria, little inhibitory effects were observed.
  • the peptides can be considered to have a more narrow spectrum of bacterial killing (Table 2).
  • Antimicrobial peptides are not potent inhibitors of Gram-positive bacteria
  • SMAP-29 variants have efficient bacterial killing and reduced cytotoxicity
  • SMAP-29 and its non-natural variants SMAP-29B and SMAP-29D were able to kill various strains of Gram-negative bacteria efficiently with reduced cytotoxicity to the human cells (see Figures 4A-E and its legend).
  • SMAP-29B and SMAP-29D were able to inhibit majority of tested Gram- negative strains. However, the cytotoxicity of these peptides was reduced, or at least not worse than the control that causes cytotoxicity, as measured by red blood cell lysis, double-strand RNA induced IL-6 production (pro-inflammation), the inhibitory effect to LPS induced cytokine production, and cell metabolism rate of MTT assay. [00254] EXAMPLE 4.
  • the non-natural SMAP-27 variants have efficient bacterial killing and reduced cytotoxicity
  • BMAP-27 and its variants BMAP-27B and BMAP-27D were able to kill various strains of Gram-negative bacteria efficiently with reduced cytotoxicity to the human cells (see Figures 5A-E and its legend).
  • SMAP-29D and BMAP-27B have very rapid bacterial killing
  • Variants SMAP-29D and BMAP-27B have more efficient bacterial killing ability as compared to the antibiotics, such as Kanamycin (See Figure 6A).
  • the rate of bacterial killing or these peptides are measured in terms of minutes, reflected by the colony forming unit reduction within 5 minutes.
  • the bacterial fold reduction for various Gram- negative strains ranges from hundreds to thousands within 5 minutes and by 3 hours of application, the visible colonies are down to tens for most of the bacterial strains tested. (See Figure 6B).
  • V. vulnificus growth curve YJ106 is greatly reduced by BMAP-27B or SMAP-
  • V. vulnificus growth measured by OD600 was inhibited in a dose-dependent manner, especially by BMAP-27B at 1 ⁇ concentration.
  • BMAP-27B was inhibited in a dose-dependent manner, especially by BMAP-27B at 1 ⁇ concentration.
  • the nearly complete inhibition by BMAP-27B to V. vulnificus at 1 ⁇ suggests that the peptide can be an efficient tool to sterilize a raw fish product.
  • BMAP-27B and SMAP-29D may interact with the Gram- negative membrane and cause the loss of the integrity of the cellular content.
  • phase contrast fluorescence microscopy with V. vulnificus treated for 5 min was performed with 4 ⁇ Fluorescein-labeled SMAP-29D ( Figure 11).
  • the FAM-labeled SMAP-29D had comparable bactericidal activity as SMAP-29D.
  • the V. vulnificus cells treated with FAM-SMAP-29D all exhibited a bulge in the membrane that typically located close to the midpoint of the cells, the site expected for bacterial binary fission to take place.
  • BMAP-27B and SMAP-29D can kill colistin-resistant bacteria.
  • BMAP-27D and SMAP-29C reduced Topl0pHNSHP45 colony formation by several logs with only a 5 minute incubation while colistin had little effect (Figure 12B).
  • BMAP-27 and SMAP-29D had comparable MICs for ToplO and
  • Topl0pHNSHP45 Although Topl0pHNSHP45 apparently does not confer cross-resistance to BMAP-27B or SMAP-29D. Furthermore, BMAP-27B and SMAP-29D could effectively kill colistin-resistant bacteria.
  • BMAP-27B Bactericidal peptides shorter than BMAP-27B or SMAP-29D that retain the activities of these peptides were generated. The reduced length should decrease the cost of synthesis and increase the efficiency of synthesis.
  • the sequence of BMAP-27B was used to generate a series of truncated peptides. A number of the peptides with truncations, amino acids substitutions were generated and tested for the killing of colistin-resistant E. coli, Topl0pHNSHP45. Two peptides were found to have improved bactericidal activity relative to BMAP-27B (Figure 13).
  • BMAP-24 that contains residues 1-24 of BMAP-27B and B22, which lacks 5 residues at the N-terminal region of BMAP-27B, reduced the number of viable colonies relative to BMAP27B. Both BMAP-24 and B22 had improved MIC against the majority of the 19 strains of Gram- negative bacteria used to select for effective cathelicidins (Table 3). Similar to BMAP-27B, BMAP-24, and B22 had higher MICs against the majority of Serratia marcescens strains. The lengths and bactericidal activities of BMAP-24 and B22 were selected for additional characterizations. [00282] Table 3. Summary of the minimal inhibitory concentrations (MIC) of B22 and BMAP-24 against 19 strains of Gram-negative bacteria. The MIC of BMAP-27 is provided as a comparator.
  • BMAP-24 and B22 remain less able to inhibit Gram- positive bacteria.
  • the MICs for two strains of S. aureus were higher than or equal to 64 ⁇ .
  • the MICs were comparable or worse than the MIC for BMAP-27B (Table 4).
  • B22 has reduced activation of Toll-like receptor 3 in vitro
  • cytotoxicity for antimicrobial peptides is the lysis of human cells.
  • B22 and BMAP-24 were tested for the lysis of human red blood cells (hRBCs). A range of concentrations from 2 to 8 ⁇ were examined. LL-37, which has previously demonstrated hRBC lysis activity, lysed hRBC when present at 4 or 8 ⁇ ( Figure 15). BMAP-24 also was able to lyse hRBC and in a concentration-dependent manner. B22, however, had only minimal hRBC lysis at concentrations up to 8 ⁇ ( Figure 15).
  • B22 can prevent lethal sepsis in mice
  • Zanetti M., "Cathelicidins, multifunctional peptides of the innate immunity.”
  • Rhouma M et al. "Colistin in pig production: chemistry, mechanism of antibacterial action, microbial resistance, and one health perspectives," Fron. Microb., 2016, 7, 1789, 22 pages.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des compositions de peptides ayant une activité bactéricide. L'invention concerne également une méthode de traitement d'infections bactériennes à l'aide de compositions comprenant des peptides bactéricides ou des variants de ceux-ci.
PCT/US2017/024766 2016-03-29 2017-03-29 Peptides bactéricides et leurs utilisations WO2017172929A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US16/146,165 US10624947B2 (en) 2016-03-29 2018-09-28 Bactericidal peptides and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662314608P 2016-03-29 2016-03-29
US62/314,608 2016-03-29

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US16/146,165 Continuation-In-Part US10624947B2 (en) 2016-03-29 2018-09-28 Bactericidal peptides and uses thereof

Publications (1)

Publication Number Publication Date
WO2017172929A1 true WO2017172929A1 (fr) 2017-10-05

Family

ID=59966431

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/024766 WO2017172929A1 (fr) 2016-03-29 2017-03-29 Peptides bactéricides et leurs utilisations

Country Status (1)

Country Link
WO (1) WO2017172929A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109232719A (zh) * 2018-09-21 2019-01-18 中国科学院理化技术研究所 一种pH响应的抗菌肽及其制备方法和应用
WO2019200378A1 (fr) * 2018-04-13 2019-10-17 The Trustees Of Indiana University Peptides bactéricides et leurs utilisations
CN112707961A (zh) * 2021-02-04 2021-04-27 中国科学院南海海洋研究所 一种贝类抗菌肽p-amp153及其应用
CN113087781A (zh) * 2021-03-30 2021-07-09 北京世华康源生物科技有限公司 一种抗菌肽及其应用
WO2022115510A1 (fr) * 2020-11-24 2022-06-02 Academia Sinica Peptides antimicrobiens et procédé de prévention ou de traitement d'une infection à l'aide de ceux-ci
US11793858B2 (en) 2018-04-13 2023-10-24 Indiana University Research And Technology Corporation Bactericidal peptides and uses thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040170642A1 (en) * 2000-08-17 2004-09-02 Jorg Fritiz Vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide of a derivative thereof
US20050058689A1 (en) * 2003-07-03 2005-03-17 Reactive Surfaces, Ltd. Antifungal paints and coatings
US20100239611A1 (en) * 2008-10-16 2010-09-23 Van Drunen Littel-Van Den Hurk Sylvia Combination adjuvant formulation
US20100316643A1 (en) * 2009-02-05 2010-12-16 The Regents Of The University Of California Targeted antimicrobial moieties
US20110250626A1 (en) * 2002-09-09 2011-10-13 Reactive Surfaces, Ltd. Visual Assays for Coatings Incorporating Bioactive Enzymes for Catalytic Functions
US20140296137A1 (en) * 2013-04-01 2014-10-02 Los Alamos National Security, Llc Methods and compositions for controlling rotifers

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040170642A1 (en) * 2000-08-17 2004-09-02 Jorg Fritiz Vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide of a derivative thereof
US20110250626A1 (en) * 2002-09-09 2011-10-13 Reactive Surfaces, Ltd. Visual Assays for Coatings Incorporating Bioactive Enzymes for Catalytic Functions
US20050058689A1 (en) * 2003-07-03 2005-03-17 Reactive Surfaces, Ltd. Antifungal paints and coatings
US20100239611A1 (en) * 2008-10-16 2010-09-23 Van Drunen Littel-Van Den Hurk Sylvia Combination adjuvant formulation
US20100316643A1 (en) * 2009-02-05 2010-12-16 The Regents Of The University Of California Targeted antimicrobial moieties
US20140296137A1 (en) * 2013-04-01 2014-10-02 Los Alamos National Security, Llc Methods and compositions for controlling rotifers

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019200378A1 (fr) * 2018-04-13 2019-10-17 The Trustees Of Indiana University Peptides bactéricides et leurs utilisations
US11793858B2 (en) 2018-04-13 2023-10-24 Indiana University Research And Technology Corporation Bactericidal peptides and uses thereof
CN109232719A (zh) * 2018-09-21 2019-01-18 中国科学院理化技术研究所 一种pH响应的抗菌肽及其制备方法和应用
CN109232719B (zh) * 2018-09-21 2021-06-29 中国科学院理化技术研究所 一种pH响应的抗菌肽及其制备方法和应用
WO2022115510A1 (fr) * 2020-11-24 2022-06-02 Academia Sinica Peptides antimicrobiens et procédé de prévention ou de traitement d'une infection à l'aide de ceux-ci
CN112707961A (zh) * 2021-02-04 2021-04-27 中国科学院南海海洋研究所 一种贝类抗菌肽p-amp153及其应用
CN112707961B (zh) * 2021-02-04 2022-06-10 中国科学院南海海洋研究所 一种贝类抗菌肽p-amp153及其应用
CN113087781A (zh) * 2021-03-30 2021-07-09 北京世华康源生物科技有限公司 一种抗菌肽及其应用
CN113087781B (zh) * 2021-03-30 2022-06-14 山东中科康源生物科技有限公司 一种抗菌肽及其应用

Similar Documents

Publication Publication Date Title
WO2017172929A1 (fr) Peptides bactéricides et leurs utilisations
Pan et al. Gene expression and localization of the epinecidin-1 antimicrobial peptide in the grouper (Epinephelus coioides), and its role in protecting fish against pathogenic infection
Jacob et al. Potential therapeutic applications of magainins and other antimicrobial agents of animal origin
Buccini et al. Antimicrobial peptides and cell-penetrating peptides for treating intracellular bacterial infections
Liu et al. Design of hybrid β-hairpin peptides with enhanced cell specificity and potent anti-inflammatory activity
AU2019222918B2 (en) Antimicrobial peptides and methods of use thereof
Ding et al. Molecular characterization of the NK-lysin in a teleost fish, Boleophthalmus pectinirostris: Antimicrobial activity and immunomodulatory activity on monocytes/macrophages
Mirski et al. Utilisation of peptides against microbial infections–a review
KR20180002710A (ko) 항균 요법
US20210246177A1 (en) Cath2 derivatives
Seo et al. Antimicrobial function of the GAPDH-related antimicrobial peptide in the skin of skipjack tuna, Katsuwonus pelamis
WO2015112980A2 (fr) Peptides antimicrobiens du type dermaseptines et piscidines
Seo et al. Antimicrobial function of SHβAP, a novel hemoglobin β chain-related antimicrobial peptide, isolated from the liver of skipjack tuna, Katsuwonus pelamis
KR101341210B1 (ko) 신규한 항균 펩타이드 및 이의 용도
Kumar et al. Antimicrobial and anti-inflammatory activities of short dodecapeptides derived from duck cathelicidin: Plausible mechanism of bactericidal action and endotoxin neutralization
Pan et al. Shrimp (Penaeus monodon) anti-lipopolysaccharide factor reduces the lethality of Pseudomonas aeruginosa sepsis in mice
TWI635095B (zh) 衍生自精胺酸密集區之經修飾抗菌胜肽
US10624947B2 (en) Bactericidal peptides and uses thereof
Wang et al. Antimicrobial Peptides from fish: Main Forces for Reducing and Substituting Antibiotics
KR101384578B1 (ko) 전복 유래의 새로운 항미생물성 펩타이드 및 이의 용도
WO2019200378A1 (fr) Peptides bactéricides et leurs utilisations
US11793858B2 (en) Bactericidal peptides and uses thereof
Desriac et al. Antimicrobial peptides from fish
TW200825098A (en) Anti-microbal peptides and uses thereof
Franco et al. OPEN ACCESS EDITED BY

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17776555

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 17776555

Country of ref document: EP

Kind code of ref document: A1